Literature DB >> 26139289

Demographic and clinical factors associated with benzodiazepine prescription at discharge from psychiatric inpatient treatment.

Shannon M Peters1, Kendra Quincy Knauf2, Christina M Derbidge3, Ryan Kimmel4, Steven Vannoy5.   

Abstract

OBJECTIVE: We sought to characterize diagnostic and treatment factors associated with receiving a prescription for benzodiazepines at discharge from a psychiatric inpatient unit. We hypothesized that engaging in individual behavioral interventions while on the unit would decrease the likelihood of receiving a benzodiazepine prescription at discharge.
METHOD: This is an observational study utilizing medical chart review (n=1007) over 37 months (2008-2011). Descriptive statistics characterized patient demographics and diagnostic/prescription frequency. Multivariate regression was used to assess factors associated with receiving a benzodiazepine prescription at discharge.
RESULTS: The sample was 61% female with mean age=40.5 (S.D.=13.6). Most frequent diagnoses were depression (54.7%) and bipolar disorder (18.6%). Thirty-eight percent of participants engaged in an individual behavioral intervention. Benzodiazepines were prescribed in 36% of discharges. Contrary to our hypothesis, individual behavioral interventions did not influence discharge benzodiazepine prescriptions. However, several other factors did, including having a substance use disorder [odds ratio (OR)=0.40]. Male sex (OR=0.56), Black race (OR=0.40) and age (OR=1.03) were nonclinical factors with strong prescribing influence.
CONCLUSION: Benzodiazepines are frequently prescribed at discharge. Our results indicate strong racial and sex biases when prescribing benzodiazepines, even after controlling for diagnosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Benzodiazepine; Health disparities; Inpatient treatment; Prescribing

Mesh:

Substances:

Year:  2015        PMID: 26139289      PMCID: PMC4630106          DOI: 10.1016/j.genhosppsych.2015.06.004

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  13 in total

Review 1.  Time to take stock: a meta-analysis and systematic review of analgesic treatment disparities for pain in the United States.

Authors:  Salimah H Meghani; Eeeseung Byun; Rollin M Gallagher
Journal:  Pain Med       Date:  2012-01-13       Impact factor: 3.750

Review 2.  American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2012-02-29       Impact factor: 5.562

Review 3.  Cognitive therapy with inpatients.

Authors:  S Stuart; J H Wright; M E Thase; A T Beck
Journal:  Gen Hosp Psychiatry       Date:  1997-01       Impact factor: 3.238

4.  Cultural-based biases of the GAD-7.

Authors:  Holly A Parkerson; Michel A Thibodeau; Charles P Brandt; Michael J Zvolensky; Gordon J G Asmundson
Journal:  J Anxiety Disord       Date:  2015-02-07

5.  Long-term effect of combined interpersonal psychotherapy and pharmacotherapy in a randomized trial of depressed patients.

Authors:  I Zobel; S Kech; D van Calker; P Dykierek; M Berger; R Schneibel; E Schramm
Journal:  Acta Psychiatr Scand       Date:  2011-01-14       Impact factor: 6.392

6.  PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.

Authors:  Simon J C Davies; Martin S Lennard; Parviz Ghahramani; Peter Pratt; Andrea Robertson; John Potokar
Journal:  J Psychopharmacol       Date:  2007-03       Impact factor: 4.153

7.  Sedative-hypnotic treatment in an acute psychiatric setting: comparison with best practice guidance.

Authors:  Amanda Wheeler; Therese Kairuz; Janie Sheridan; Emma McPhee
Journal:  Pharm World Sci       Date:  2007-03-01

8.  Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders: findings from the Netherlands Study of Depression and Anxiety (NESDA).

Authors:  Lynn Boschloo; Nicole Vogelzangs; Johannes H Smit; Wim van den Brink; Dick J Veltman; Aartjan T F Beekman; Brenda W J H Penninx
Journal:  J Affect Disord       Date:  2011-01-19       Impact factor: 4.839

9.  Benzodiazepine use in the United States.

Authors:  Mark Olfson; Marissa King; Michael Schoenbaum
Journal:  JAMA Psychiatry       Date:  2015-02       Impact factor: 21.596

Review 10.  Goals of inpatient treatment for psychiatric disorders.

Authors:  Steven S Sharfstein
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

View more
  6 in total

1.  Examining racial/ethnic differences in patterns of benzodiazepine prescription and misuse.

Authors:  Benjamin Cook; Timothy Creedon; Ye Wang; Chunling Lu; Nicholas Carson; Piter Jules; Esther Lee; Margarita Alegría
Journal:  Drug Alcohol Depend       Date:  2018-03-26       Impact factor: 4.492

2.  Factors associated with benzodiazepine prescribing in community mental health settings.

Authors:  Lauren Jessell; Victoria Stanhope; Jennifer I Manuel; Pedro Mateu-Gelabert
Journal:  J Subst Abuse Treat       Date:  2019-11-22

3.  Patient race and opioid misuse history influence provider risk perceptions for future opioid-related problems.

Authors:  Adam T Hirsh; Tracy M Anastas; Megan M Miller; Patrick D Quinn; Kurt Kroenke
Journal:  Am Psychol       Date:  2020-09

4.  Factors associated with sedative use and misuse among heroin users.

Authors:  Tabitha E H Moses; Leslie H Lundahl; Mark K Greenwald
Journal:  Drug Alcohol Depend       Date:  2018-02-02       Impact factor: 4.492

5.  Misuse of benzodiazepines: Prevalence and impact in an inpatient population with psychiatric disorders.

Authors:  Arnaud Panes; Hélène Verdoux; Annie Fourrier-Réglat; Driss Berdaï; Antoine Pariente; Marie Tournier
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

6.  Benzodiazepine and z-hypnotic prescribing from acute psychiatric inpatient discharge to long-term care in the community.

Authors:  Chris F Johnson; Ola Ali Nassr; Catherine Harpur; David Kenicer; Alex Thom; Gazala Akram
Journal:  Pharm Pract (Granada)       Date:  2018-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.